Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2023-09-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea by '주식회사 큐로셀' (Curocell Inc.). It details the offering of 1,600,000 shares of common stock, provides investment risk factors, and outlines the company's business model and financial outlook. This is a formal regulatory filing for a public offering, which falls under the category of Regulatory Filings (RNS) as it is a primary document for securities registration.
2023-09-13 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive financial report titled '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for the company '주식회사 큐로셀'. It includes the independent auditor's report, balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes to the financial statements for the fiscal year ending December 31, 2022. Since this is a standalone audit report containing full financial statements and notes, it falls under the 'Audit Report / Information' category. FY 2022
2023-04-03 Korean
감사보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Curocell' (주식회사 큐로셀) for the fiscal year ending December 31, 2021. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is a standalone audit report document rather than a full 10-K annual report or a simple earnings release. Therefore, it fits the 'Audit Report / Information' category. FY 2021
2022-04-04 Korean
감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'Curocell' (주식회사 큐로셀) for the fiscal year ending December 31, 2020. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a full financial audit report, not an earnings release or a summary, and it is not an announcement of a report (RPA). FY 2020
2021-04-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.